Actinium Pharmaceuticals, Inc. (ATNM)

1.780.01 (-0.56%)

Actinium Pharmaceuticals, Inc. (ATNM) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

High Bankruptcy RiskBelow Average ESGFair ValuationLow ProfitabilityAdequate Financial HealthInefficient OperationsModerate GrowthLow QualityAdequate Dividend ProfileIndustry Rank: 20.71%Sector Rank: 20.11%

AMEX - Healthcare - Biotechnology | Market Cap: 55.53M | Next Earnings Date: 13 Nov 2025

Day's Range

1.75 - 1.81

52-Week Range

1.03 - 2.41

Volume

122.5K / 296.7K (Avg.)

P/E Ratio | EPS

-1.36 | -1.31

Trending:

ATNM Fundamental Risk Analysis - Compare Against AVXL

Comparison against AVXL

None AGEN AVXL RVPH AXSM TRAW

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.05

Increased from previous period

D/E of 0.05 while AVXL has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.

Net Debt-to-EBITDA

9.77

Increased from previous period

Net debt 50-75% of AVXL's 11.26. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.

Interest Coverage Ratio

No Data

No Data available this quarter, please select a different quarter.

Current Ratio

9.14

Decreased from previous period

Similar current ratio to AVXL's 8.86. Guy Spier would investigate if industry liquidity norms make sense for both companies.

Intangibles-to-Total-Assets Ratio

No Data

No Data available this quarter, please select a different quarter.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric:

ATNM Fundamental Risk Analysis - Compare Against AVXL

Comparison against AVXL

None AGEN AVXL RVPH AXSM TRAW

Debt-to-Equity Ratio

0.05

Increased from previous period

D/E of 0.05 while AVXL has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.

Net Debt-to-EBITDA

9.77

Increased from previous period

Net debt 50-75% of AVXL's 11.26. Mohnish Pabrai would check if this competitive advantage in leverage translates to better reinvestment opportunities.

Interest Coverage Ratio

No Data

No Data available this quarter, please select a different quarter.

Current Ratio

9.14

Decreased from previous period

Similar current ratio to AVXL's 8.86. Guy Spier would investigate if industry liquidity norms make sense for both companies.

Intangibles-to-Total-Assets Ratio

No Data

No Data available this quarter, please select a different quarter.

+ Add New Metric (Coming Soon)

Add more metric or remove existing ones, customize as per your preference, feature coming soon!

Select Chart Metric: